Medline (NASDAQ:MDLN) Research Coverage Started at The Goldman Sachs Group

The Goldman Sachs Group started coverage on shares of Medline (NASDAQ:MDLN) in a report released on Monday morning, MarketBeat reports. The firm issued a buy rating and a $49.00 target price on the stock.

Several other analysts also recently commented on MDLN. Royal Bank Of Canada assumed coverage on Medline in a research note on Monday. They issued an “outperform” rating and a $47.00 price objective for the company. Bank of America began coverage on Medline in a report on Monday. They set a “buy” rating and a $50.00 price target for the company. BNP Paribas Exane began coverage on Medline in a research note on Monday. They set a “neutral” rating and a $38.00 price objective on the stock. Cowen began coverage on shares of Medline in a report on Monday. They set a “buy” rating on the stock. Finally, Baird R W upgraded shares of Medline to a “strong-buy” rating in a research note on Monday. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $46.70.

Medline Stock Up 1.3%

MDLN opened at $43.41 on Monday. Medline has a fifty-two week low of $34.89 and a fifty-two week high of $45.50.

Insiders Place Their Bets

In other Medline news, Director Charles N. Mills acquired 2,579,310 shares of Medline stock in a transaction on Thursday, December 18th. The stock was purchased at an average price of $29.00 per share, for a total transaction of $74,799,990.00. Following the purchase, the director directly owned 2,441,379 shares of the company’s stock, valued at $70,799,991. This trade represents a -1,870.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Andrew J. Mills bought 2,586,206 shares of the firm’s stock in a transaction dated Thursday, December 18th. The shares were acquired at an average cost of $29.00 per share, with a total value of $74,999,974.00. Following the completion of the transaction, the director owned 2,586,206 shares in the company, valued at approximately $74,999,974. The trade was a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

Key Stories Impacting Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Several major brokers initiated bullish coverage or set high price targets (Truist $52, Evercore $50, BTIG $50, Goldman $49, Sanford Bernstein $49, UBS $48, RBC $47, BMO $45, Leerink/Baird strong-buy). Those reports signal upward earnings/market-share expectations and provide concrete upside targets for investors, supporting the rally. Analyst Coverage & Targets (Benzinga)
• Neutral Sentiment: Widespread coverage initiations across big banks (Deutsche Bank, Jefferies, Wells Fargo, JPMorgan, Citigroup, Barclays, Mizuho, TD Cowen, Wolfe Research, Rothschild/Redburn, BNP Paribas Exane) increase the stock’s visibility and institutional research footprint—likely to lift liquidity and investor interest over time but not an immediate fundamental change on its own. Coverage Initiations (AmericanBankingNews)
• Neutral Sentiment: Press coverage highlighting a strong market debut and “aging dividend” thematic interest has helped momentum traders and retail investors take notice; this amplifies the technical lift but is not new company-specific fundamental news. Market Debut Coverage (NAI500)
• Negative Sentiment: Not all firms are uniformly bullish—BNP Paribas and Rothschild/Redb issued “hold” ratings for now. These more cautious views could cap near-term upside if other analysts temper forecasts or if results miss elevated expectations. Hold Ratings (Zacks)

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.